Home > Insider Trading > Filing (0001209191-21-018932)

Filing Details

Accession Number:: 0001209191-21-018932
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-03-09 16:02:06
Reporting Period:: 2021-03-08

Accepted Time:: 2021-03-09 16:02:06
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1434316	Fate Therapeutics Inc	FATE	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1586892	D Daniel Shoemaker	C/O Fate Therapeutics, Inc.; 3535 General Atomics Court #200 San Diego CA 92121	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2021-03-08	3,298	$78.60	94,722	No	4	S	Direct
Common Stock	Disposition	2021-03-08	4,627	$79.58	90,095	No	4	S	Direct
Common Stock	Disposition	2021-03-08	5,174	$80.73	84,921	No	4	S	Direct
Common Stock	Disposition	2021-03-08	2,993	$81.60	81,928	No	4	S	Direct
Common Stock	Disposition	2021-03-08	2,480	$83.46	79,448	No	4	S	Direct
Common Stock	Disposition	2021-03-08	2,728	$84.20	76,720	No	4	S	Direct
Common Stock	Disposition	2021-03-08	2,900	$85.50	73,820	No	4	S	Direct
Common Stock	Disposition	2021-03-08	800	$86.70	73,020	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020.
Represents the weighted average sale price of the shares sold ranging from $78.08 to $79.02 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
Represents the weighted average sale price of the shares sold ranging from $79.09 to $80.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
Represents the weighted average sale price of the shares sold ranging from $80.12 to $81.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
Represents the weighted average sale price of the shares sold ranging from $81.19 to $82.15 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
Represents the weighted average sale price of the shares sold ranging from $82.74 to $83.68 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
Represents the weighted average sale price of the shares sold ranging from $83.775 to $84.76 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
Represents the weighted average sale price of the shares sold ranging from $84.99 to $85.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.